培美曲塞联合顺铂在晚期乳腺癌中的应用  

Pemetrexed in combination with cisplatin in the treatment of advanced breast cancer application

作　　者：岳丽娟[1] 侯新丽[1] 薛辉[1] 薛玲[1] 高翔[1] 沈勇[1] 袁亮[1] 张晶晶[1] 朱宏财 

机构地区：[1]陕西省汉中市中心医院肿瘤内科,723000

出　　处：《国际肿瘤学杂志》2014年第7期545-548,共4页Journal of International Oncology

摘　　要：目的：研究培美曲塞联合顺铂方案治疗晚期乳腺癌的近期临床疗效和不良反应。方法采用信封法随机分为治疗组和对照组。治疗组18例晚期乳腺癌用培美曲塞联合顺铂方案治疗，对照组23例晚期乳腺癌用吉西他滨联合顺铂治疗，21 d为一个周期。按世界卫生组织（WHO）关于实体瘤治疗疗效评价标准和化疗毒性评价标准（CTCAE），判断近期疗效和药物的不良反应。结果治疗组的肿瘤控制率为83．3％（15/18），对照组为78．3％（18/23），两组差异无统计学意义（χ2＝0．00094，P＞0．05）；而治疗组和对照组的不良反应比较，两组差异均有统计学意义（骨髓抑制χ2＝9．23；疲乏χ2＝4．96；恶心、呕吐χ2＝4．98；腹泻χ2＝4．45；皮疹χ2＝5．03，P均＜0．05）。结论培美曲塞联合顺铂方案对晚期乳腺癌患者具有很好的疗效，且不良反应低。Objective Tostudyrecentclinicalefficacyandadversereactionsofpemetrexedincombi-nationwithcisplatininthetreatmentofadvancedbreastcancer.Methods Usingenvelopesandrandomlythe patients were dividing into treatment group and control group.The treatment group with 1 8 cases of advanced breast cancer were treated with pemetrexed and cisplatin while in the control group ,23 cases advanced breast cancer patients were treated with gemcitabine and cisplatin with 21 days as a cycle.The efficacy and adverse re-actions were determined according to the WHO on Response Evaluation Criteria in Solid Tumors therapy and chemotherapytoxicityevaluationcriteria.Results Tumorcontrolrateinthetreatmentgroupwas83.3%（1 5/1 8）,while in the control group was 78.3%（1 8/23 ）,and the difference was not statistically significant （χ2 =0.000 94,P〉0.05）;while the adverse reactions differenced between the treatment group and the con-trol group were statistically significant（bone marrow suppression χ2 =9.23;fatigue χ2 =4.96;nausea and vomi-tingχ2=4.98;diarrheaχ2=4.45;skinrashχ2=5.03,P〈0.05）.Conclusion Pemetrexedcombinedwith cisplatin in patients with advanced breast cancer has a good effect,and the adverse reaction is low.

关 键 词：顺铂 乳腺肿瘤 治疗应用 

分 类 号：R737.9[医药卫生—肿瘤]